Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for BRIACELL THERAP (BCTX : NSDQ)
 
 • Company Description   
BriaCell Therapeutics Corp. is an immuno-oncology focused biotechnology company. It developed a patented whole-cell vaccine, cancer immunotherapy technology called the `BriaVax` vaccine for cancer. The company's technology consists of Bria-IMT(TM), Bria-OTS(TM) and BriaDx(TM) which are in clinical stage. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.

Number of Employees:

 
 • Price / Volume Information   
Yesterday's Closing Price: $5.52 Daily Weekly Monthly
20 Day Moving Average: 10,561,238 shares
Shares Outstanding: 7.54 (millions)
Market Capitalization: $41.60 (millions)
Beta: 1.08
52 Week High: $9.00
52 Week Low: $2.81
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 75.80% 73.90%
12 Week 43.01% 33.94%
Year To Date 32.37% 17.22%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
3RD FLOOR BELLEVUE CENTRE 235-15TH STR
-
WEST VANCOUVER,A1 V7T 2X1
CAN
ph: 604-921-1810
fax: 604-921-1898
None http://www.briacell.com
 
 • General Corporate Information   
Officers
William V. Williams - President; Chief Executive Officer and Director
Jamieson Bondarenko - Chairman of the Board of Directors
Gadi Levin - Chief Financial Officer and Secretary
Charles Louis Wiseman - Founder and Director
Farrah Dean - Mang. of Corp. Devel.

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 10778Y302
SIC: 2834
Fiscal Year
Fiscal Year End: July
Last Reported Quarter: 01/01/21
Next Expected EPS Date: 07/05/21
Share - Related Items
Shares Outstanding: 7.54
Most Recent Split Date: 1.00 (0.00:1)
Beta: 1.08
Market Capitalization: $41.60 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 07/05/21  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 79.40%
vs. Previous Quarter: 4.65%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
04/30/21 - -
01/31/21 - -
10/31/20 - -
ROA
04/30/21 - -
01/31/21 - -371.38
10/31/20 - -605.71
Current Ratio
04/30/21 - -
01/31/21 - 0.05
10/31/20 - 0.06
Quick Ratio
04/30/21 - -
01/31/21 - 0.05
10/31/20 - 0.06
Operating Margin
04/30/21 - -
01/31/21 - -
10/31/20 - -
Net Margin
04/30/21 - -
01/31/21 - -
10/31/20 - -
Pre-Tax Margin
04/30/21 - -
01/31/21 - -
10/31/20 - -
Book Value
04/30/21 - -
01/31/21 - -0.64
10/31/20 - -4.70
Inventory Turnover
04/30/21 - -
01/31/21 - -
10/31/20 - -
Debt-to-Equity
04/30/21 - -
01/31/21 - -
10/31/20 - -
Debt-to-Capital
04/30/21 - -
01/31/21 - -
10/31/20 - -
 

Powered by Zacks Investment Research ©